药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Cinolazepam
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Varicella Zoster Vaccine (Live/attenuated)
The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Rubella virus vaccine
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
TG4010
The therapeutic efficacy of TG4010 can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Vitespen
The therapeutic efficacy of Vitespen can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
GI-5005
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
SRP 299
The therapeutic efficacy of SRP 299 can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Rindopepimut
The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
INGN 225
The therapeutic efficacy of INGN 225 can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
PEV3A
The therapeutic efficacy of PEV3A can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
G17DT
The therapeutic efficacy of G17DT can be decreased when used in combination with Hydrocortisone butyrate.
Cinolazepam
Acetyldigoxin
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Acetyldigoxin.
Cinolazepam
Gitoformate
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Gitoformate.
Cinolazepam
Lanatoside C
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Lanatoside C.